Table 1. . miRNAs associated with doxorubicin resistance.
| miRNA | Change in resistant tumor | Cell type | Target gene(s) | Ref. |
|---|---|---|---|---|
| miR-215 | ↑ | Hepatocyte | DHFR, TS | [111] |
| miR-26b | ↓ | Hepatocyte | TAK1, TAB3 | [58] |
| miR-122 | ↑ | Hepatocyte | Cyclin G1 | [106] |
| miR-199a–3p | ↓ | Hepatocyte | mTOR, c-Met | [110] |
| miR-519d | ↑ | Hepatocyte | P21, PTEN, AKT3, TIMP2 | [112] |
| miR-101 | ↓ | Hepatocyte | EZH2 | [109] |
| miR-223 | ↓ | Hepatocyte | ABCB1 | [108] |
| Let–7a | ↑ | Hepatocyte, SCC | Caspase–3 | [125] |
| miR-138 | ↓ | HNSCC | MDR1 | [126] |
| miR-21 | ↑ | Breast | PTEN | [127] |
| miR-760 | ↓ | Breast | RHOB, ANGPTL4, ABCA1 | [128] |
| miR-218 | ↓ | Breast | Survivin | [129] |
| miR-298 | ↓ | Breast | MDR1 | [130] |
| miR-450b–3p | ↓ | Breast | HER3 | [131] |
| miR-451 | ↓ | Breast | MDR1 | [132] |
| miR-452 | ↓ | Breast | IGF–1R | [133] |
| miR-200c | ↓ | Breast | ZEB1 | [134] |
| miR-34a | ↓ | Breast | NOTCH1 | [135] |
| miR-34c | ↓ | Osteosarcoma | NOTCH1, LEF1 | [136] |
| miR-382 | ↓ | Osteosarcoma | HIPK3 | [137] |
| miR-301a | ↑ | Osteosarcoma | AMPKα1 | [138] |
| miR-708 | ↓ | Ewing sarcoma | EYA3 | [139] |
| miR-125b | ↑ | Ewing sarcoma | P53, BAK | [140] |
| miR-522 | ↓ | Colon | ABCB5 | [141] |
| miR-101 | ↓ | Colon | SphK1 | [142] |
| miR-195 | ↓ | Colon | Bcl-w | [143] |
| miR-103/107 | ↓ | Gastric | Cav–1 | [144] |
| miR-508–5p | ↓ | Gastric | ABCB1, ZNRD1 | [145] |
| miR-331–5p | ↓ | Leukemia | MDR1 | [146] |
| miR-27a | ↓ | Leukemia | MDR1 | [146] |
DHFR: Dihydrofolate reductase; TS: Thymididylate synthase; Cav–1: Caveolin–1; SCC: Squamous cell carcinoma; HNSCC: Head and neck SCC.